Author Interviews, Infections, Lancet, Urinary Tract Infections / 27.10.2018
Successful Trial of Cefiderocol For Resistant & Complicated Urinary Tract Infections
MedicalResearch.com Interview with:
Simon Portsmouth, MD
Senior Medical Director
Shionogi Inc.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Antibiotics for multidrug resistant Gram-negative infections are desperately needed. Cefiderocol is the first siderophore antibiotic to reach patients.
Siderophore antibiotics bind to free iron and use the bacterial active iron transport channels to cross the outer membrane of Gram-negative bacteria. Laboratory studies have shown that cefiderocol is active against multi-drug resistant Gram-negative bacteria, often where no other antibiotics are active. It is able to overcome most types of antibiotic resistance due to its active transport into cells and stability against all carbapenemases.
The need for antibiotics for carbapenem resistant Gram-negative infections is described as a critical need by the WHO. This trial was the first in humans with serious infections and demonstrated excellent efficacy in a complicated patient population where almost ¼ were over 75 years of age. Additionally cefiderocol did not appear to have any safety problems, and was well tolerated.
(more…)
